Epidemiology and outcomes of cardiac arrest among children with Down Syndrome: a multicenter analysis

Asif Padiyath1, Mallikarjuna Rettiganti2, Jeffrey M Gossett2

  • 1Division of Pediatric Cardiology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Minerva Anestesiologica
|December 24, 2016
PubMed

Insights

Children with Down syndrome have a higher risk of cardiac arrest but lower mortality after cardiac arrest compared to peers. This study examines cardiac arrest incidence and outcomes in critically ill children with and without Down syndrome.

Area of Science:

  • Pediatric Critical Care Medicine
  • Cardiology
  • Genetics and Genomics

Background:

  • Down syndrome prevalence is increasing globally.
  • Outcomes after pediatric cardiac arrest (CA) in children with Down syndrome are not well-established.
  • This study evaluates CA epidemiology and mortality in critically ill children with and without Down syndrome.

Purpose of the Study:

  • To assess the association between Down syndrome and the incidence of cardiac arrest in critically ill children.
  • To determine the impact of Down syndrome on mortality rates following cardiac arrest in pediatric intensive care units.
  • To analyze the epidemiological differences in cardiac arrest and its outcomes between children with and without Down syndrome.

Main Methods:

  • Utilized data from the Pediatric Health Information Systems (PHIS) database from 2004-2014.
  • Included pediatric patients (≤18 years) admitted to participating Intensive Care Units.
  • Employed multivariable logistic regression to adjust for patient and center characteristics.

Main Results:

  • Analyzed 849,250 patients; 25,143 had Down syndrome.
  • Patients with Down syndrome showed a higher likelihood of cardiac arrest (OR: 1.14, P=0.01).
  • Despite higher CA incidence, patients with Down syndrome had lower in-hospital mortality post-cardiac arrest (OR: 0.78, P=0.02).

Conclusions:

  • Incidence of cardiac arrest and post-arrest mortality vary significantly between children with and without Down syndrome.
  • Children with Down syndrome face a higher risk of cardiac arrest but experience better survival rates after arrest.
  • Further research is warranted to understand the mechanisms behind these observed differences in outcomes.
Abstract

Related Concept Videos

Cardiopulmonary Resuscitation I: Adult01:21

Cardiopulmonary Resuscitation I: Adult

Cardiopulmonary resuscitation, or CPR, is a life-saving emergency procedure performed when a person's heart has stopped beating or they are no longer breathing. The foundation of CPR is Basic Life Support (BLS), which focuses on the early recognition of cardiac arrest, the immediate start of high-quality chest compressions, and the timely use of an automated external defibrillator (AED).Assessing Responsiveness and Checking the Carotid PulseWhen approaching an unresponsive person, first ensure...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...